Sponsored Links
| Compugen Announces Positive Therapeutic Effects Of Novel Peptide In Animal Model Of Inflammatory Bowel Disease |
 |
 |
 |
| Medical News - Irritable-Bowel Syndrome | |||
|
Compugen Ltd. (NASDAQ:CGEN) announced that CGEN-25007, a novel peptide antagonist of gp96 with potent anti-inflammatory activity, has shown positive therapeutic effects in an animal model of inflammatory bowel disease (IBD), a commonly used term covering ulcerative colitis and Crohn's disease. CGEN-25007 was initially discovered using Compugen's Disease-Associated Conformation (DAC) blockers discovery platform. Read more: Irritable-Bowel Syndrome News From Medical News Today
|